Chromocell Therapeutics announces amendment to stock repurchase plan

Chromocell Therapeutics (CHRO) board of directors has authorized an amendment to the Company’s existing stock repurchase plan to increase the total value of shares of Chromocell’s common stock available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.